| abstract |
The invention relates to the new compounds 1,2,4- and 1,3,4-thiadiazoles and oxadiazoles as well as 1,2,4-triazoles substituted by 4,6-tertiary dibutyl-5-hydroxy-pyrimidine, as well as additions and their pharmaceutically acceptable base salts, pharmaceutical compositions containing them, as well as their methods of use. It has been discovered that the compounds of the invention exhibit a 5-lipoxygenase and / or cyclooxygenase inhibitor activity offering a possibility of treatment by said inhibition of disorders such as inflammation, arthritis, pain, fever and including rheumatoid arthritis, osteoarthritis, other inflammatory disorders, psoriasis, allergic diseases, asthma, inflammatory bowel infections, gastrointestinal ulcers, cardiovascular disorders, including ischemic heart disease and atherosclerosis , as well as a deterioration of the cells induced by ischemia, in particular a deterioration of the brain caused by an attack. They can also be used locally to treat acne, sunburn, psoriasis and eczema. Leukotriene-induced pulmonary, gastrointestinal, inflammatory, dermatological and cardiovascular disorders can also be treated. The compounds of the invention also have potential utility as antioxidants induced by leukotrienes. The preferred use is in the treatment of inflammatory disorders. Thus, the invention also constitutes a pharmaceutical composition or a process for producing a pharmaceutical composition intended for use in the treatment of the abovementioned pathological disorders. |